Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Splenomegaly is a clinical surrogate of oxaliplatin-induced sinusoidal obstruction syndrome (SOS). We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients. Materials and Methods Splenomegaly was determined by spleen volumetry using computed tomography images obtained before initiation of chemotherapy and after completion of adjuvant FOLFOX in CRC patients. Ten genetic polymorphisms in 4 SOS-related genes (VEGFA, MMP9, NOS3, and GSTP1) were analyzed using DNA from peripheral blood mononuclear cells. Results Of 124 patients included, increase in spleen size was observed in 109 (87.9%). Median change was 31% (range, –42% to 168%). Patients with splenomegaly had more severe thrombocytopenia compared to patients without splenomegaly during the chemotherapy period (p < 0.0001). The cumulative dose of oxaliplatin and the lowest platelet count during the chemotherapy period were clinical factors associated with splenomegaly. However, no significant associations were found between genetic polymorphisms and development of splenomegaly. Disease-free survival was similar regardless of the development of splenomegaly. Conclusion Splenomegaly was frequently observed in patients receiving adjuvant FOLFOX and resulted in more severe thrombocytopenia but did not influence treatment outcome. Examined genetic polymorphisms did not predict development of splenomegaly.
Abstract
Purpose Splenomegaly is a clinical surrogate of oxaliplatin-induced sinusoidal obstruction syndrome (SOS). We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients. Materials and Methods Splenomegaly was determined by spleen volumetry using computed tomography images obtained before initiation of chemotherapy and after completion of adjuvant FOLFOX in CRC patients. Ten genetic polymorphisms in 4 SOS-related genes (VEGFA, MMP9, NOS3, and GSTP1) were analyzed using DNA from peripheral blood mononuclear cells. Results Of 124 patients included, increase in spleen size was observed in 109 (87.9%). Median change was 31% (range, –42% to 168%). Patients with splenomegaly had more severe thrombocytopenia compared to patients without splenomegaly during the chemotherapy period (p < 0.0001). The cumulative dose of oxaliplatin and the lowest platelet count during the chemotherapy period were clinical factors associated with splenomegaly. However, no significant associations were found between genetic polymorphisms and development of splenomegaly. Disease-free survival was similar regardless of the development of splenomegaly. Conclusion Splenomegaly was frequently observed in patients receiving adjuvant FOLFOX and resulted in more severe thrombocytopenia but did not influence treatment outcome. Examined genetic polymorphisms did not predict development of splenomegaly.
참고문헌 (25)
- Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62, pp.10~29 (2012)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011", Cancer Research and Treatment, 46(2), pp.109~123 (2014), 대한암학회
- Choti MA, "Trends in long-term survival following liver resection for hepatic colorectal metastases", Ann Surg, 235, pp.759~766 (2002)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
- Rubbia-Brandt L, "Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer", Ann Oncol, 15, pp.460~466 (2004)
- Nakano H, "Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy", Ann Surg, 247, pp.118~124 (2008)
- Angitapalli R, "Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer", Oncology, 76, pp.363~368 (2009)
- Overman MJ, "Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury", J Clin Oncol, 28, pp.2549~2555 (2010)
- Vreuls CP, "Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer", Br J Cancer, 108, pp.676~680 (2013)
- Levitsky J, "Hepatic complications of hematopoietic cell transplantation", Curr Gastroenterol Rep, 9, pp.60~65 (2007)
- Vauthey JN, "Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases", J Clin Oncol, 24, pp.2065~2072 (2006)
- Rubbia-Brandt L, "Sinusoidal obstruction syndrome", Clin Liver Dis, 14, pp.651~668 (2010)
- Rubbia-Brandt L, "Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis", Histopathology, 56, pp.430~439 (2010)
- Soubrane O, "Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases : correlation with post-hepatectomy outcome", Ann Surg, 251, pp.454~460 (2010)
- van den Broek MA, "Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases", Ann Surg Oncol, 20, pp.1462~1469 (2013)
- DeLeve LD, "Characterization of a reproducible rat model of hepatic veno-occlusive disease", Hepatology, 29, pp.1779~1791 (1999)
- Iguchi A, "Vascular endothelial growth factor(VEGF)is one of the cytokines causative and predictive of hepatic venoocclusive disease(VOD)in stem cell transplantation", Bone Marrow Transplant, 27, pp.1173~1180 (2001)
- Ribero D, "Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatinbased chemotherapy for colorectal liver metastases", Cancer, 110, pp.2761~2767 (2007)
- Jung EJ, "Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma", Anticancer Res, 32, pp.3357~3362 (2012)
- Jardim DL, "Oxaliplatin-related thrombocytopenia", Ann Oncol, 23, pp.1937~1942 (2012)
- Rubbia-Brandt L, "Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans", Mol Cancer Ther, 10, pp.687~696 (2011)
- Agostini J, "Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation", J Hepatol, 56, pp.869~876 (2012)
- Tamandl D, "Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy", Ann Surg Oncol, 18, pp.421~430 (2011)
- Vreuls CP, "Hepatic sinusoidal obstruction syndrome(SOS)reduces the effect of oxaliplatin in colorectal liver metastases", Histopathology, 61, pp.314~318 (2012)